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Mycobacterium kansasii is the second most common nontuberculous mycobacteria
(NTM) after the Mycobacterium avium complex in the United States and Japan,
1,2
and is the most common cause of NTM lung disease in the United Kingdom and
Western Europe.
3,4 Infection with M. kansasii probably occurs via an aerosol
route. Moreover, unlike other NTM, M. kansasii is much more difficult to recover
from natural water supplies.
5 Tap water is likely a major reservoir for M. kansasii
causing human infection, and thus an association may exist between clinical
disease and potable water supplies.
Mycobacterium kansasii usually presents as lung disease that is nearly identical
to tuberculosis. Cavitation was found in about 90% of cases in older reports,
6-8
while recent survey of 56 adults with M. kansasii lung disease in Israel between
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Purpose: While Mycobacterium kansasii is a common cause of nontuberculous
mycobacterial (NTM) lung disease in many developed countries, M. kansasii is
infrequently isolated in Korea. We investigated the clinical and radiological
features and treatment outcomes of M. kansasii lung disease in Korea retrospec-
tively. Materials and Methods: We identified 41 patients with M. kansasii lung
disease who met the diagnostic criteria for NTM lung disease in two tertiary
referral hospitals in Seoul, Korea, between January 1998 and December 2007.
Results: Their median age was 63 years [interquartile range (IQR) 51-75 years]
and 33 (81%) were men. Twenty-three patients (56%) were smokers and 13
patients (32%) had previous pulmonary tuberculosis. The most common radiogra-
phic findings were nodules (n = 22, 54%) and consolidation (n = 22, 54%).
Cavitation was present in 13 patients (32%). Thirty-one patients (76%) were
treated with isoniazid, rifampin, and ethambutol. The median treatment duration
was 16 months (IQR 9-18 months). The negative conversion rate after 12 months
of treatment was 95%. Conclusion: Clinicians should be aware of the various
radiographic manifestations of M. kansasii lung disease. With appropriate
treatment, these patients have a good prognosis.
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INTRODUCTION1999 and 2004 noted cavitation in 54% only.
9 A variety of
radiologic findings have been reported in M. kansasii lung
disease, including non-cavitary or nodular/bronchiectatic
lesions.
10,11
In Korea, M. kansasii is infrequently isolated and a rela-
tively uncommon cause of NTM lung disease.
12-15 Although
small numbers of cases have been reported,
16,17 little is
known about the detailed clinical and radiological charac-
teristics or treatment outcomes in Korea. This study inves-
tigated the clinical and radiological features and treatment
outcomes of M. kansasii lung disease in Korea.
Study subjects
This retrospective study included 41 patients with M. kan-
sasii lung infection who attended two tertiary referral hos-
pitals in Seoul, Korea, between January 1998 and December
2007: Samsung Medical Center and Asan Medical Center.
All patients met the diagnostic criteria of NTM lung
disease,
1 and we reviewed their medical records and radio-
graphs. This study was approved by the institutional review
board of Samsung Medical Center and Asan Medical
Center, both of which waived the requirement for informed
consent of the individual patients due to the retrospective
nature of the study.
Microbiological examination
Mycobacterial stains and cultures were performed using
standard methods.
18 The results of smear microscopy were
reported semiquantitatively. A positive smear was defined
as one with > 1 acid-fast bacilli (AFB) per 100 high-power
fields. Respiratory specimens were decontaminated using
N-acetyl-L-cysteine/2% NaOH, and processed specimens
were plated onto 3% Ogawa medium. Inoculated tubes
were incubated at 37˚C and then inspected weekly for 8
weeks. To distinguish between M. tuberculosis and NTM,
all AFB isolates were assessed according to growth rates,
colony morphology, and pigmentation, as well as with a
commercial polymerase chain reaction-based assay system
(MTB-ID; M&D, Wonju, Korea). NTM species were iden-
tified using a polymerase chain reaction and restriction
fragment length polymorphism methods based on the rpoB
gene, as described previously.
14
Evaluation of clinical and radiographic findings
The medical records of all study patients were reviewed,
including information such as age, sex, body mass index
(BMI), respiratory and constitutional symptoms, smoking
history, underlying illness, pulmonary function tests,
tuberculosis history, results for human immunodeficiency
virus (HIV) antibody, and treatment history. 
Chest radiographs and computed tomography (CT)
images were those obtained closest in time to the date of the
first positive respiratory culture result. The chest X-ray and
CT images were evaluated in terms of the presence of no-
dules, consolidation, cavitation, and pleural effusion. In
addition, hilar or mediastinal lymphadenopathy and bron-
chiectasis was evaluated on CT.
Nodules (≤ 3 cm in diameter) were considered present
when a rounded opacity was observed, either well or poorly
defined. Consolidation was defined as a homogeneous inc-
rease in pulmonary parenchymal attenuation that obscures
the margins of vessels and airway walls. A cavity was re-
garded as present when a gas-filled space was seen within
pulmonary consolidation, a mass, or a nodule. Bronchie-
ctasis was defined as bronchial dilatation relative to the
accompanying pulmonary artery, a lack of tapering of
bronchi, and bronchi identified within 1 cm of the pleural
surface.
19
The distribution (upper vs. middle and lower lung zone)
and laterality (unilateral vs. bilateral infiltrates) of the lung
lesions were also analyzed. Lesions were considered to be
in the upper zone of the lung if cephalad to the aortic arch, in
the lower zone if caudad to the inferior pulmonary vein,
and in the middle zone if between these two zones.
20
Assessment of microbiological responses
Sputum conversion was defined as three consecutive nega-
tive cultures within 6 months, with the time of conversion
defined as the date of the first negative culture. If the patient
could not expectorate sputum during the treatment period,
the sputum was considered to have converted to negative.
Sputum relapse was defined as two consecutive positive
cultures after sputum conversion.
21
Clinical characteristics
The baseline characteristics of the patients are shown in
Table 1. The median age was 63 years [interquartile range
(IQR) 51-75 years] and 33 (81%) were men. Twenty-three
(56%) patients were current or ex-smokers. None of the
patients were HIV positive. Comorbid conditions included
previous pulmonary tuberculosis in 13 (32%) patients,
chronic obstructive pulmonary disease in 13 (32%), under-
lying malignancy in nine (22%), and diabetes mellitus in
two (5%). The most common presenting symptoms were
cough (n = 27, 66%) and sputum (n = 26, 63%). Ten (24%)
patients had dyspnea and four (10%) had hemoptysis. 
The diagnosis was confirmed by obtaining an adequate
number of positive sputum cultures (n = 37, 90%). Patients,
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MATERIALS AND METHODS
RESULTSwho were either unable to produce sputum or had negative
sputum cultures, were diagnosed using bronchial aspirates
(n = 3, 7%) or lung tissues (n = 1, 2%). Sputum AFB smear
examinations were positive in 11 patients (27%). Testing
for rifampin susceptibility was performed on M. kansasii
isolates recovered from 28 patients and 89% (25/28) were
susceptible to rifampin.
Radiographic and CT findings
All 41 patients had abnormal chest radiographic findings at
the time of diagnosis (Table 2). The most common radio-
graphic findings were nodules (n = 22, 54%) and consoli-
dation (n = 22, 54%). Cavitation was present in 13 patients
(32%) and pleural effusion in four (10%). Radiographic
abnormalities were confined to the upper lung zones in 15
patients (37%), and 21 patients (51%) had bilateral disease.
A chest CT was available in 36 patients (88%). The most
common CT finding was nodules (n = 25, 69%). Consoli-
dation and cavitation were present in 16 patients each (44%
each). Combined bronchiectasis was found in 12 patients
(33%). 
Management of patients
Ten (24%) patients did not receive anti-mycobacterial drugs
after the diagnosis of M. kansasii disease. Of these, eight
patients had mild symptoms and no significant change on
their radiographs during the follow-up period. One patient
was lost to the follow-up 1 month after the diagnosis. The
upper lobar consolidation resolved spontaneously without
antibiotic therapy in one patient (Table 3).
Thirty-one (76%) patients received antibiotic therapy
including isoniazid, rifampin, and ethambutol. Of these, 16
patients completed the treatment and were followed for a
median of 13 months (IQR 7-28 months) without relapse.
Sputum relapse occurred after treatment completion in one
patient who had no history of pulmonary tuberculosis and
the isolate of M. kansasii was sensitive to rifampin. Four
patients remained on the treatment as of the end of May
2009. Nine patients were lost to the follow-up after anti-
biotic therapy for a median of 6 months (IQR 2-10 months)
and two patients died of causes unrelated to M. kansasii
lung disease during antibiotic therapy (Table 3). Three
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Table 1. Clinical Characteristics of 41 Patients with M. kansa-
siiLung Disease
Variables Number (%)
Age, yrs 63 (51 - 75) 
Male 33 (81)
Body mass index, kg/m
2 20 (18.3 - 22.6)
Current or ex-smoker 23 (56)
Comorbid conditions
Tuberculosis history 13 (32)
Chronic obstructive pulmonary disease 13 (32)
Malignancy 9 (22)






Weight loss 2 (5)
Fever 2 (5)
The data are presented as the median (interquartile range) or number (%).












Hilar or mediastinal lymphadenopathy 3 (8)
Bronchiectasis 12 (33)
Pleural effusion 3 (8)
Distribution
Upper lung zone(s) 15 (37)




*Chest CT was available in 36 patients.
Table 3. Management of 41 Patients with M. kansasii Lung 
Disease
Management Number (%)
Followed without antibiotic therapy 10 (24)
No significant changes  8
Improved 1
Lost to follow-up 1
Antibiotic therapy 31 (76)
Treatment completion and cure 16
Remained on the treatment 4
Lost to follow-up during treatment 9
Death during treatment* 2
*Two patients died of causes unrelated to M. kansasii lung disease during 
antibiotic therapy. patients had rifampin-resistant M. kansasii lung disease.
One patient was lost to follow-up after 1.5 months of
therapy with isoniazid, rifampin, and ethambutol before
drug susceptibility results were available. Treatment regi-
mens were changed to clarithromycin and levofloxacin in
two patients after the confirmation of resistance to rifampin.
However, one patient was lost to the follow-up and the
other patient died of causes unrelated to M. kansasii lung
disease during antibiotic therapy.
The median time for negative culture conversion was 1
month (IQR 1-3 months) in patients who achieved negative
conversion. For 21 patients who received antibiotic therapy
for more than 12 months, the median treatment duration
was 16 months (IQR 9-18 months) and the 12-month cul-
ture conversion rate was 95% (20/21).
In Korea, M. kansasii constitutes only 2-4% of NTM
organisms isolated from clinical specimens,
13-15 although
the isolation of M. kansasii has increased steadily in recent
years.
15 In this study, we found that M. kansasii lung
disease had diverse radiographic findings. Nodules and
consolidation were the most common radiographic features,
while cavitation was seen on the chest X-ray in only 32%
of patients. A rifampin-containing three-drug regimen was
effective, especially in patients treated for more than 12
months.
The radiographic features of M. kansasii lung disease
are frequently reported as being indistinguishable from
those of tuberculosis.
8,22,23 Older studies found cavitation in
75-96% of patients with M. kansasii lung disease,
3,8,23-25
while the proportion of cavitary lesions was about 50% in
recent studies.
9,17 In our series, cavitation was seen in only
32% of patients on chest X-rays. This discrepancy might
be explained by recent improvements in the diagnosis and
microbiological isolation of the organism.
9 Moreover, some
studies have reported that patients with M. kansasii lung
disease can present with non-cavitary or nodular/bron-
chiectatic lesions as a major features of M. avium complex
lung disease, which is the most common etiology of NTM
lung disease.
3,10,11
In addition to the low proportion of cavitation, we found
that M. kansasii lung disease had diverse radiographic
features. Upper lobe lesions were not predominant and
pleural effusions were seen in four patients (10%). NTM
infection is rarely accompanied by pleural involvement,
although a few case reports have described pleural effusion
caused by M. kansasii.
26-28 Pleural effusion was associated
with parenchymal consolidation in three of four patients in
our study. On the chest CT, more nodular and cavitary
lesions surrounded by consolidation were found in these
patients. 
Regarding the antibiotic treatment for M. kansasii lung
disease, a three-drug combination consisting of isoniazid,
rifampin, and ethambutol is recommended and these anti-
biotics should be maintained for at least 12 months after
negative sputum conversion.
1 The key to successful therapy
for M. kansasii lung disease is to include rifampin in a
multidrug regimen. Adding isoniazid and ethambutol to
rifampin is essential for preventing the emergence of resis-
tance to rifampin.
9
A prospective trial of 28 patients compared treatment for
12 or 18 months with this three-drug regimen.
29 Only one
relapse occurred; the patient was in the 12-month chemo-
therapy group. In a series of 56 adults with M. kansasii
lung disease in Israel, the mean treatment duration was 21
± 7 months.
9 Another case series of 75 patients with M.
kansasii lung disease in Spain showed that a 12-month
multidrug treatment regimen, including isoniazid, rifampin,
and ethambutol, supplemented with streptomycin during
the first 2-3 months, was effective in most cases of M.
kansasii lung disease, although five patients (7%) relapsed.
30 
We found that the rifampin-based multidrug regimen
was effective, especially in patients treated for more than
12 months. Those patients had a 95% culture conversion
rate after a median treatment duration of 18 months. Rela-
pse occurred in one patient. However, the relapse rate may
be an underestimate because the loss to follow-up was
high in our study.
In summary, the radiographic characteristics of M. kan-
sasii lung disease in recently diagnosed patients are diverse
in Korea. Nodules and consolidation are found more fre-
quently than cavitary lesions. A three-drug combination
regimen containing rifampin for more than 12 months is
effective in patients with M. kansasii lung disease.
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